Treatment issues in interstitial lung disease in tropical countries

Current Opinion in Pulmonary Medicine

Volumn 5, Issue 5, 1999, Pages 287-292

  Jindal, Surinder K ^a   Gupta, Dheeraj ^a   Aggarwal, Ashutosh N ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

AGE; AGED; CLASSIFICATION; DEVELOPING COUNTRY; DISEASE COURSE; DRUG COST; ECONOMICS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LYMPHOCYTE; PATHOLOGY; PROGNOSIS; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; TROPIC CLIMATE;

ADRENAL CORTEX HORMONES; AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS; DEVELOPING COUNTRIES; DISEASE PROGRESSION; DRUG COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; LYMPHOCYTES; PROGNOSIS; PULMONARY FIBROSIS; SURVIVAL RATE; TREATMENT OUTCOME; TROPICAL CLIMATE;

EID: 0033193093     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199909000-00004     Document Type: Article

References (44)

1. Jindal SK, Gupta D: Incidence and recognition of interstitial pulmonary fibrosis in developing countries. Curr Opin Pulm Med 1997, 3:378-382.
2. Jindal SK, Gupta D: Algorithm for diagnosing pulmonary fibrosis in tropical countries. Curr Opin Pulm Med 1998, 4:294-299. This paper reviews various diagnostic methods and suggests a practical approach to diagnosis that is especially useful in developing countries.
3. Jindal SK, Gupta D: Long term oxygen therapy. In Oxygen Therapy, edn. 1. Chandigarh: Pulmonary CME Program, Chandigarh; 1998:111-120.
4. Johnston ID, Prescott RJ, Chaimers JC, Rudd RM: Fibrosing Alveolitis Sub-Committee of the Research Committee of British Thoracic Society. Study of cryptogenic fibrosing alveolitis: current presentations and initial management. Thorax 1997, 52:38-44. This report summarizes the practices adopted by physicians for the treatment of IPF. Almost half of patients receive no treatment after initial diagnosis.
5. Ryu JH, Colby TV, Hartman TE: Idiopathic pulmonary fibrosis: current concepts. Mayo Clin Proc 1998, 73:1085-1101. This excellent review covers not only diagnosis and treatment but also pathology, pathogenesis, and other aspects of IPF.
6. Turner-Warwick M, Burrows B, Johnson A: Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980, 35:593-599.
7. Winterbauer RH, Hammar SP, Hallman KO, Haye JE, Pardee NE, Morgan EH, et al.: Diffuse interstitial pneumonitis: clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med 1978, 65:661-672.
8. Meier-Sydow J, Weiss SM, Buhl R, Rust M, Raghu G: Idiopathic pulmonary fibrosis: current clinical concepts and challenges in management. Semin Respir Crit Care Med 1994, 15:77-96.
9. Erbes R, Schaberg T, Loddenkemper R: Lung function tests in patients with idiopathic pulmonary fibrosis: are they helpful in predicting outcome? Chest 1997, 111:51-57. This article has special relevance for developing countries. It shows the usefulness of standard spirometric tests in assessing prognosis.
10. Wells AU, Rubens MB, DuBois RM, Hansell DM: Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. Am J Radiol 1993, 161:1159-1165.
11. Hansell DM, Wells AU: CT evaluation of fibrosing alveolitis applications and insights. J Thorac Imaging 1996, 11:231-249.
12. Turner-Warwick M, Haslam PL: The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1987, 135:26-34.
13. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniak RM: A clinical, radiographic and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986, 133:97-103.
14. Mapel DW, Samet JM, Coultas DB: Corticosteroids and the treatment of idiopathic pulmonary fibrosis: past, present and future. Chest 1996, 110:1058-1067. This review addresses issues related to corticosteroid therapy for IPF. It focuses on current experience with this treatment and on questions that need to be answered in clinical studies of IPF.
15. Hunninghake GW, Kalica AR: Workshop summary: approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 1993, 151:915-918.
16. Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR, Reynolds HY: Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiological, scintigraphic, cytologic and biochemical aspects. Ann Intern Med 1976, 85:769-788.
17. Carrington CB, Gaensler EA, Coutu RE, FitzGerald MX, Gupta RG: Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978, 298:801-809.
18. Behera D, Gupta D, Jindal SK: Response to steroid therapy in patients of idiopathic pulmonary fibrosis: a retrospective analysis. Ind J Chest Dis Allied Sci 1998, 40:163-169.
19. Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M: Randomized controlled trial comparing prednisolone along with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989, 44:280-288.
20. Raghu G, Dapaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, et al.: azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double blind randomized placebo-controlled clinical trial. Am Rev Respir Dis 1991, 144:291-296.
21. Kolb M, Kirschner J, Riedel W, Wirtz H, Schmidt M: Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. Eur Respir J 1998, 12:1409-1414. Although this is a retrospective analysis, it provides useful information on intermittent cyclophosphamide therapy, which was shown to be of value in patients with a vital capacity greater than 50% of predicted and a shorter duration of illness.
22. Varai G, Earle L, Jimenez SA, Steiner RM, Varga J: A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998, 25:1325-1329.
23. Moolman JA, Bardin PG, Rossouw DJ, Joubert JR: Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 1991, 46:592-595.
24. Jindal SK, Sharma BK: High altitude induced alveolitis: an unusual case [abstract]. In Proceedings of IV World Congress of Adaptive Medicine. Chandigarh: Postgraduate Institute of Medical Education and Research; 1995:70.
25. Sauty A, Rochat TH, Schoch OD, Hamacher J, Kurt A-M, Dayer J-M, Nicod LP: Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J 1997, 10:2907-2912.
26. Bauer EA, Valle KJ: Colchicine induced modulation of collagenase in human skin fibroblast cultures: I. Stimulation of enzyme synthesis in normal cells. J Invest Dermatol 1982, 79:398-403.
27. Entzian P, Schlaak M, Seitzer U, Bufe A, Acil Y, Zabel P: Anti-inflammatory and anti-fibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung 1997, 175:41-51.
28. Peters SG, McDougall JC, Douglas WW, Coles DT, DeRemee RA: Colchicine in the treatment of pulmonary fibrosis. Chest 1993, 103:101-104.
29. Douglas WW, Ryu JH, Swensen SJ, Offord KP, Schroeder DR, Caron GM, DeRemee RA: Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 158:220-225.
30. Selman M, Carrillo G, Salas J, Padilla RP, Perez-Chavira R, Sansores R, Chapela R: Colchicine, D-penicillamine and prednisone in the treatment of idiopathic pulmonary fibrosis. Chest 1998, 114:507-512.
31. Steen VD, Medsger TAJ, Rodnan GP: D-penicillamine therapy in progressive systemic sclerosis: a retrospective analysis. Ann Intern Med 1982, 97:652-659.
32. Iyer SN, Margolin SB, Hyde DM, Giri SN: Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin hamster model. Exp Lung Res 1998, 24:119-132.
33. MacNee W, Rahman I: Oxidants/antioxidants in idiopathic pulmonary fibrosis. Thorax 1995, 50(suppl I):S53-S58.
34. Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C: Antioxidative and clinical effects of high dose N-acetylcysteine in fibrosing alveolitis. Am J Respir Crit Care Med 1997, 158:1897-1901.
35. Coker RK, Laurent GJ: Pulmonary fibrosis: cytokines in the balance. Eur Respir J 1998, 11:1218-1221.
36. Zabel P, Entzian P, Dalhoff K, Schlaak M: Pentoxifylline in the treatment of sarcoidosis. Am J Respir Crit Care Med 1997, 155:1665-1669.
37. Fishman RHB: Kosher chickens, rabbits' ears and a scar free future. Lancet 1997, 350:570.
38. Gay SE, Kazerooni EA, Toews GB, Lynch JP 3d, Gross BH, Cascade PN, et al.: Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998, 157:1063-1072. This prospective study was done to identify pretreatment features that could be used to predict short-term improvement in pulmonary function and improved long-term survival.
39. Schwartz D, Helmers R, Galvin J, Uan Fossen D, Frees K, Dayton C, et al.: Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994, 149:450-454.
40. Mapel DW, Hunt WC, Utton R, Baumgartner KB, Samet JM, Coultas DB: Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax 1998, 53:469-476. The study compares the median survival of patients in a population-based Registry with that of a case-control cohort. Survival did not differ from that seen in the 1960s and 1970s.
41. Jindal SK, Gupta D: Diagnosis and management of sarcoidosis: current trends. In Postgraduate Medicine, edn. 1. Edited by Bansal BC. New Delhi: Yogesh Pracashan; 1997:347-352.
42. Jindal SK, Whig J: Silicosis in developing countries. In Occupational Lung Disease: An International Perspective. Edited by Banks DE, Parker JE. London: Chapman and Hall; 1998: 213-218. This is a comprehensive review of the causes, spectrum, and management of silicosis and silicotuberculosis in developing countries.
43. Vijayan VK, Sankaran K, Sharma SK, Misra NP: Chronic lung inflammation in victims of toxic gas leak at Bhopal. Respir Med 1995, 89:105-111.
44. Gupta D, Aggarwal AN, Jain S, Behera D, Jindal SK: Acute pulmonary effects of toxic nitrogen dioxide fume inhalation. Respir Care 1998, 43:557-561.